Pancreatic Cancer Research

ResearcherYokohama City University Medical CenterActive in the last 2 years

Manabu Morimoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3940-9634; OpenAlex author ID A5023693285, A5101457577. Sources: OpenAlex.

Their work

Papers
38 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
57
Papers, trials and grants by year

2014: 1 paper · 2015: 7 papers · 2016: 6 papers · 2017: 3 papers · 2018: 5 papers · 2019: 1 paper · 2020: 4 papers · 2021: 1 paper · 2022: 6 papers · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper

Papers 38

  1. Real-world evidence of chemotherapy effects in advanced pancreatic ductal adenocarcinoma: prognostic significance of TP53 status in gemcitabine plus nab-paclit… Co-author DOI 10.1016/j.esmogo.2025.100221↗
  2. Liposomal irinotecan plus fluorouracil/leucovorin in older patients with advanced pancreatic cancer: a single-center retrospective study. Co-author DOI 10.1007/s10147-023-02432-9↗
  3. FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational… Co-author DOI 10.1186/s12885-023-10654-3↗
  4. Risk factors for early recurrence in patients with pancreatic ductal adenocarcinoma who underwent curative resection. Co-author DOI 10.1186/s12957-023-03141-3↗
  5. Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second-line treatment regimen for unresectable pancreatic cancer: A real-world analysi… Co-author DOI 10.1002/cam4.4512↗
  6. Postoperative acute pancreatitis after pancreatic resection in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00423-022-02481-0↗
  7. Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study. Co-author DOI 10.1016/j.pan.2022.06.004↗
  8. Randomized Phase II Study of Gemcitabine Monotherapy vs. Gemcitabine with an EPA-Enriched Oral Supplement in Advanced Pancreatic Cancer. Co-author DOI 10.1080/01635581.2020.1871495↗
  9. Sarcopenia: Prognostic Value for Unresectable Pancreatic Ductal Adenocarcinoma Patients Treated With Gemcitabine Plus Nab-Paclitaxel. Co-author DOI 10.1097/mpa.0000000000001985↗
  10. Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus … Co-author DOI 10.3892/ol.2022.13495↗
  11. Tissue factor and its procoagulant activity on cancer-associated thromboembolism in pancreatic cancer. Co-author DOI 10.1111/cas.15106↗
  12. Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer. Co-author DOI 10.1038/s41467-020-16711-w↗
  13. A Multicenter Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Elderly Patients With Advanced Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000001484↗
  14. Clinical Implication of Pre-operative C-reactive Protein-Albumin Ratio as a Prognostic Factor of Patients With Pancreatic Ductal Adenocarcinoma: A Single-insti… Co-author DOI 10.21873/invivo.11780↗
  15. The age-adjusted Charlson comorbidity index is an independent prognostic factor in pancreatic cancer patients who receive curative resection followed by adjuva… Co-author DOI 10.4103/jcrt.jcrt_440_18↗
  16. The impact of SPARC expression on the survival of pancreatic ductal adenocarcinoma patients after curative resection. Co-author DOI 10.7150/jca.28660↗
  17. Prediction model for pancreatic cancer risk in the general Japanese population. Co-author DOI 10.1371/journal.pone.0203386↗
  18. The Lymph Node Ratio Is an Independent Prognostic Factor in Pancreatic Cancer Patients Who Receive Curative Resection Followed by Adjuvant Chemotherapy. Co-author DOI 10.21873/anticanres.12801↗
  19. Safety and feasibility of enhanced recovery after surgery in the patients underwent distal pancreatectomy for pancreatic cancer. Co-author DOI 10.4103/0973-1482.183186↗
  20. Survival and the prognosticators of peritoneal cytology-positive pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy. Co-author DOI 10.4103/0973-1482.194927↗
  21. Predictive value of ERCC1, ERCC2, ERCC4, and glutathione S-Transferase Pi expression for the efficacy and safety of FOLFIRINOX in patients with unresectable pa… Co-author PMID 30416859↗
  22. Clinical implications of ribonucleotide reductase subunit M1 in patients with pancreatic cancer who undergo curative resection followed by adjuvant chemotherap… Co-author DOI 10.3892/ol.2017.5935↗
  23. Predictive role of human equilibrative nucleoside transporter 1 in patients with pancreatic cancer treated by curative resection and gemcitabine-only adjuvant … Co-author DOI 10.3892/ol.2017.6220↗
  24. Clinical implications of dihydropyrimidine dehydrogenase expression in patients with pancreatic cancer who undergo curative resection with S-1 adjuvant chemoth… Co-author DOI 10.3892/ol.2017.6295↗
  25. Duodenal stenting followed by systemic chemotherapy for patients with pancreatic cancer and gastric outlet obstruction. Last author DOI 10.1016/j.pan.2016.07.007↗
  26. Unexpected Side Effects of a High S-1 Dose: Subanalysis of a Phase III Trial Comparing Gemcitabine, S-1 and Combinatorial Treatments for Advanced Pancreatic Ca… Last author DOI 10.1159/000446989↗
  27. Locked Nucleic Acid In Situ Hybridization Analysis of MicroRNA-21 Predicts Clinical Outcome in Patients After Resection for Pancreatic Cancer Treated with Adju… Co-author PMID 26977002↗
  28. The Surgical Apgar Score Is an Independent Prognostic Factor in Patients with Pancreatic Cancer Undergoing Pancreatoduodenectomy Followed by Adjuvant Chemother… Co-author PMID 27127164↗
  29. [A Case of Pancreatic Cancer Associated with Autoimmune Pancreatitis]. Co-author PMID 27760963↗
  30. [Safety and Feasibility of Pancreatic Surgery for Pancreatic Cancer in Elderly Patients]. Co-author PMID 28133043↗
  31. Safety and feasibility of S-1 adjuvant chemotherapy for pancreatic cancer in elderly patients. Co-author DOI 10.1007/s00280-015-2736-5↗
  32. Potential prognostic significance of a new proteomic profile in patients with advanced pancreatic adenocarcinoma. Last author DOI 10.1016/j.pan.2015.07.003↗
  33. Genome-wide association study-identified SNPs (rs3790844, rs3790843) in the NR5A2 gene and risk of pancreatic cancer in Japanese. Co-author DOI 10.1038/srep17018↗
  34. Impact of postoperative complications on survival and recurrence in pancreatic cancer. Co-author PMID 25862906↗
  35. Clinical implication of peritoneal cytology in the pancreatic cancer patients who underwent curative resection followed by adjuvant gemcitabine or S-1 chemothe… Co-author PMID 25911897↗
  36. Lymphatic invasion is an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with gemci… Co-author PMID 25916085↗
  37. Glasgow Prognostic Score Predicts Clinical Outcomes in Patients with Pancreatic Cancer Undergoing Adjuvant Gemcitabine Monotherapy After Curative Surgery. Last author PMID 26254380↗
  38. Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for resected pancreatic cancer. Co-author DOI 10.1007/s00280-014-2601-y↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Makoto Ueno · 34 shared papers, 2014–2024 · strength 2.96
  2. Satoshi Kobayashi · 25 shared papers, 2014–2024 · strength 2.37
  3. Soichiro Morinaga · 24 shared papers, 2014–2023 · strength 1.66
  4. Masaaki Murakawa · 21 shared papers, 2014–2023 · strength 1.42
  5. Toru Aoyama · 20 shared papers, 2014–2020 · strength 1.18
  6. Shin Maeda · 7 shared papers, 2018–2025 · strength 1.08
  7. Shun Tezuka · 9 shared papers, 2016–2023 · strength 0.97
  8. Shuhei Nagashima · 6 shared papers, 2021–2024 · strength 0.93
  9. Naoto Yamamoto · 12 shared papers, 2014–2023 · strength 0.90
  10. Yuichiro Tozuka · 5 shared papers, 2018–2024 · strength 0.67
  11. Shinichi Ohkawa · 9 shared papers, 2014–2022 · strength 0.66
  12. Hiroshi Tamagawa · 6 shared papers, 2018–2023 · strength 0.63
  13. Takashi Oshima · 9 shared papers, 2015–2020 · strength 0.53
  14. Yohei Miyagi · 7 shared papers, 2016–2021 · strength 0.50
  15. Hiroyuki Asama · 3 shared papers, 2022 · strength 0.42
  16. Yuto Kamioka · 3 shared papers, 2020–2023 · strength 0.39
  17. Junji Furuse · 2 shared papers, 2023–2024 · strength 0.38
  18. Shinnosuke Kawahara · 2 shared papers, 2022–2023 · strength 0.29
  19. Makoto Sugimori · 2 shared papers, 2018–2025 · strength 0.28
  20. Mariko Kamiya · 3 shared papers, 2018–2020 · strength 0.25
  21. Masakatsu Numata · 3 shared papers, 2018–2020 · strength 0.24
  22. Masanori Oshi · 1 shared paper, 2025 · strength 0.21
  23. Hajime Yamazaki · 1 shared paper, 2025 · strength 0.21
  24. Yoshimasa Suzuki · 1 shared paper, 2025 · strength 0.21
  25. Takashi Kaneko · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.